"We are entering a pivotal time for the Company", CEO5 Nov 2020 07:28
N4P" is pleased to update that it has successfully developed different options to make a fully monodispersed formulation of Nuvec® loaded with plasmid DNA. Initial studies have also demonstrated that Nuvec® loaded with a plasmid DNA can be dried, stored at room temperature and reconstituted without any degradation of DNA".
This is very encouraging news for N4P shareholders i would say. And so is the following from the RNS:
"This formulation is now being stored over different periods after which it will be reconstituted and tested in vitro to demonstrate transfection has been maintained. Demonstrating formulation stability would be an important milestone given that stable, easy to store and easy to use vaccines are a major challenge for developers".
Sounds good and so does the following sentence from the RNS:
"The Directors believe that demonstrating Nuvec® can be consistently formulated with DNA or mRNA and dry stored for later use would give Nuvec® a considerable commercial advantage as a delivery technology compared to lipid based mRNA systems that require substantial freezing or electroporation based DNA systems which are expensive and difficult to use. As this work concludes the Company will look to incorporate the key findings into the planned optimised in vivo study.
Nigel Theobald, Chief Executive Officer of the Company, commented:
"We are pleased to have made significant strides with our optimisation work and are currently analysing the findings. We are examining how these will feed into the optimised strand of the pending in vivo study. The unoptimised side of this, which involves our first full in vivo study utilising the Coronavirus DNA plasmid, is due to commence imminently.
"Taken together with the work into oral applications and the ongoing technology transfer for the manufacture of Nuvec®, we are entering a pivotal time for the Company over the next six months and I look forward to providing further updates as each work stream progresses."
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.
Fingers crossed all the pieces of the jigsaw are coming together for N4P along with the update today in the RNS re Covid.
Good luck, Brighty
Sign In
Follow the stocks
